Roche Hit as Oral Weight-Loss Drug Candidate Shows Side Effects

Roche’s stock fell after new data from an early-stage clinical trial of its closely watched oral weight-loss drug candidate prompted analysts to question the company’s potential to quickly enter a booming obesity market.